WHO Guideline on GLP-1 Therapies for Treatment of Obesity in Adults—Reply

Francesca Celletti; Jeremy Farrar; Luz De Regil

doi:10.1001/jama.2026.0687

March 26, 2026JAMA

WHO Guideline on GLP-1 Therapies for Treatment of Obesity in Adults—Reply

View at Publisher

Ask AI

Bookmark

Share

Key Points

Address comments and provide clarification regarding the World Health Organization guideline on using glucagon-like peptide-1 (GLP-1) therapies to treat obesity in adults.
Synthesizes expert panel consensus, systematic review evidence, and methodological frameworks underpinning the World Health Organization recommendations.
Reaffirms the therapeutic role and clinical indications for GLP-1 receptor agonists in managing adult obesity across global healthcare settings.
Clarifies critical considerations surrounding equitable medication access, long-term safety, and integration with lifestyle interventions.

No abstract yet

We only have this paper's title and publication details.

Read it at the source

Ask about this paper

Answers are grounded in this paper and cite their sources.

Implication

Clinical correspondence reports recommendations for GLP-1 therapies in adults with obesity, highlighting the importance of standardized treatment guidelines.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Celletti et al. (2026) studied this question.

synapsesocial.com/papers/69f1244dd0e13c1ffb21bd39 https://doi.org/10.1001/jama.2026.0687

View at Publisher

Ask AI

Bookmark

Share

WHO Guideline on GLP-1 Therapies for Treatment of Obesity in Adults—Reply

Key Points

No abstract yet

Ask about this paper

Implication

Discussion

Cite This Study

WHO Guideline on GLP-1 Therapies for Treatment of Obesity in Adults—Reply

Key Points

No abstract yet

Ask about this paper

Implication

Discussion

Cite This Study

Keep reading

Keep reading